Spatiotemporal Control of Vascular Endothelial Growth Factor Expression Using a Heat-Shock-Activated, Rapamycin-Dependent Gene Switch by Martín-Saavedra, Francisco M. et al.
Spatiotemporal Control of Vascular Endothelial Growth
Factor Expression Using a Heat-Shock-Activated,
Rapamycin-Dependent Gene Switch
Francisco M. Martı´n-Saavedra,1–3 Christopher G. Wilson,3 Richard Voellmy,4,5
Nuria Vilaboa,1,2 and Renny T. Franceschi3
Abstract
A major challenge in regenerative medicine is to develop methods for delivering growth and differentiation
factors in specific spatial and temporal patterns, thereby mimicking the natural processes of development and
tissue repair. Heat shock (HS)-inducible gene expression systems can respond to spatial information provided by
localized heating, but are by themselves incapable of sustained expression. Conversely, gene switches activated
by small molecules provide tight temporal control and sustained expression, but lack mechanisms for spatial
targeting. Here we combine the advantages of HS and ligand-activated systems by developing a novel
rapamycin-regulated, HS-inducible gene switch that provides spatial and temporal control and sustained ex-
pression of transgenes such as firefly luciferase and vascular endothelial growth factor (VEGF). This gene circuit
exhibits very low background in the uninduced state and can be repeatedly activated up to 1 month. Further-
more, dual regulation of VEGF induction in vivo is shown to stimulate localized vascularization, thereby pro-
viding a route for temporal and spatial control of angiogenesis.
Introduction
Tissue development and regeneration are highlycoordinated events requiring exquisite control over the
sequence, concentration, timing, and distribution of regener-
ative factors. For example, in fracture healing many mole-
cules, including cytokines, bone morphogenetic proteins
(BMPs), and angiogenic factors, are expressed in distinct
temporal sequences and have unique spatial distributions
within the fracture callous (Gerstenfeld et al., 2003; Yu et al.,
2010). In nonhealing fractures and trauma-induced high-
volume tissue defects, these spatially and temporally encoded
signals are absent or attenuated. A major challenge for re-
generative medicine, therefore, is to develop approaches for
temporal and spatial control of growth factor delivery that
will mimic these natural events to jumpstart and guide tissue
regeneration.
While some progress has been made designing protein
delivery systems that can release factors in a controlled
manner (King and Krebsbach, 2012), gene therapy offers
major advantages in this regard. Initial uses of this technol-
ogy in orthopedic regeneration employed vectors that con-
stitutively expressed growth factors and BMPs under the
control of strong viral promoters to stimulate regeneration of
cartilage, bone, muscle, and tendons. Much of this work was
recently reviewed (Steinert et al., 2008; Meloni et al., 2010;
Kimelman Bleich et al., 2012; Nixon et al., 2012). Using this
approach, successful healing of large segmental bone defects
was achieved. More recently, several regulated gene ex-
pression systems have been developed, thereby providing
the potential to more tightly control the timing and se-
quence of regenerative factor delivery. These genetic tools
typically contain two elements: (1) a transactivator or tran-
sinhibitor regulated by an exogenous element (usually a
small-molecule ligand), and (2) a gene of interest controlled
by a transactivator-responsive or transinhibitor-susceptible
promoter. Included in this toolbox are gene switches regu-
lated by tetracycline-responsive elements, transactivators
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derived from steroid receptors, and synthetic transcription
factors activated by rapamycin or blue light (Vilaboa et al.,
2011; Wang et al., 2012). For example, tetracycline-/doxycy-
cline-regulated expression of BMPs was shown to induce
bone formation at both ectopic and orthopic sites (Moutsat-
sos et al., 2001; Peng et al., 2004, 2005). Using this approach,
bone regeneration was demonstrated in both spinal fusion
and segmental defect animal models (Moutsatsos et al., 2001;
Hasharoni et al., 2005). Rapamycin-responsive gene expres-
sion systems represent an additional approach to regulated
gene expression that provides lower background and higher
inducibility relative to other ligand-activated systems. These
systems use a synthetic transactivator composed of separate
DNA-binding and activation domains that cannot interact.
Only after a dimerizer (rapamycin or related nonimmuno-
suppressive analogs) is added will the separate components
form a functional transcription factor. In this way, very tight
control over transgene expression is achieved. Our previous
work demonstrated the efficacy of this approach as a means
of stringently regulating the magnitude and temporal pat-
tern of BMP-2 expression in vivo, which resulted in uniform
bone healing of a critical-sized calvarial defect (Koh et al.,
2006).
While providing good temporal control, small-ligand-
regulated systems cannot by themselves regulate the spatial
distribution of transgene expression. To achieve this, it is
necessary to use promoters capable of responding to tar-
getable, externally directed physical stimuli such as localized
heating. The heat shock protein (Hsp) gene promoters are
particularly well suited to this purpose (Welch, 1993; Cotto
and Morimoto, 1999). Heating can be achieved by a variety
of methods, such as direct application of a localized thermal
stimulus or by using high-intensity ultrasound, which can be
focused to small volumes. The human HSP70B promoter,
which exhibits extremely low basal activity and high heat
inducibility (Dreano et al., 1986), has been successfully used
to target several transgenes in vivo (Braiden et al., 2000;
Vekris et al., 2000; Smith et al., 2002; Deckers et al., 2009).
However, because it is susceptible to thermal activation as-
sociated with local inflammation or fever, it does not provide
the necessary stringency for gene therapy applications. This
promoter is also rapidly deactivated upon withdrawal of the
hyperthermic stimulus, thus limiting the capacity for the heat
shock (HS) pathway to drive sustained expression of thera-
peutic transgenes. To address these issues, we developed a
dual-requirement-inducible system wherein the HSP70B
promoter is used to drive expression of a ligand-activated
transcription factor that subsequently activates a target gene
only when the activating ligand is present. To demonstrate
the feasibility of this strategy, we constructed a regulatory
circuit that used a hybrid promoter containing the human
HSP70B promoter and GAL4-responsive elements to drive
expression of a mifepristone-activated chimeric transacti-
vator, GLp65, and, as a second component, a luciferase re-
porter gene linked to a GAL4-responsive promoter. In vivo
heat activation, combined with administration of mifepris-
tone, induced reporter activity, which was maintained by
addition of mifepristone and reversed after withdrawal of
the drug (Vilaboa et al., 2005).
Here we describe the development of a second gene
expression system that combines HS induction with the
specificity, low background, and high inducibility of
rapamycin-regulated systems to control human vascular
endothelial growth factor (hVEGF), a key factor in vasculo-
genesis and angiogenesis (Semenza, 2007). As will be shown,
this system provides stringent control over transgene ex-
pression in vitro and in vivo and induces the synthesis of high
levels of biologically active VEGF in experimental animals.
Materials and Methods
Vector construction
A sequence containing a tandem of 12 ZFHD1-binding
sites was PCR-amplified from construct pZ12I-PL-2 using
primers 5¢-TAAGGCGCGCCAGGTACCGAGCTCTTAC and
5¢-TATGGCGCGCCTTATGGGGGTGTCAAAATG, digested
with AscI and inserted in an AscI-cut Hsp70/GAL4-fLuc
plasmid. The resulting construct was named Hsp70/
12xZFHD1-flucS2. An Hsp70/12xZFHD1 cassette was ex-
cised from Hsp70/12xZFHD1-flucS2 using BamHI and Hin-
dIII and subcloned in pcDNA 3.1( - ) (Invitrogen, Barcelona,
Spain). The resulting plasmid was digested with BglII and
BamHI to remove CMV promoter sequences, and ligated to
prepare Hsp70/12xZFHD1. EcoRI and BamHI sites were in-
serted in Hsp70/12xZFHD1 by the QuickChange procedure
(Agilent, Madrid, Spain) using primers 5¢-CGACAAGAA
GCTTAAGTTGGATCCGCTGATCAGCCTCGAC and 5¢-CG
CAGCATCCGACAAGAATTCTAAGTTGGATCCGCTGATCA,
respectively. The resulting plasmid was digested with EcoRI
and BamHI and ligated to an EcoRI/BamHI fragment from
pC4N2-RHS3H/ZF3, a plasmid containing sequences coding
for the two-component rapamycin-binding transcription
factor (TA). The resulting plasmid was designated pL2N2-
pHsp70/12xZFHD1-TA. The fragment containing Hsp70/
12xZFHD1 promoter, TA coding, and the adjacent BGH
poly(A) sequences was flanked by ClaI sites using the
QuickChange procedure and primers 5¢-GCTGCTGAAGCT
GGAGACTAGTTAATATCGATACGGCTGTGGAATGT and
5¢-ATTCCAGAAGCCACCATCGATTATCCTGCTGCCAA
GAG. The resulting construct was digested with ClaI and
ligated to the larger fragment of a ClaI-cut pL2N2-RHS3H/
ZF3 construct in which EcoRI and BamHI sites have been
previously replaced by ClaI sites in a QuickChange reaction.
Primers employed were 5¢-GGATCTCCCGATCCATCGAT
GTCAGGTGGCACTT and 5¢-AGTGTAGCGGTATCGAT
GCGCGTAACCACCACACCCG. To prepare pZ12-fLuc,
pGL-Basic (Promega, Madison, WI) was digested with
HindIII and BamHI to recover firefly luciferase (fLuc) coding
sequences and the adjacent SV40 poly(A) sequence and then
ligated to the larger HindIII–BamHI fragment of pZ12-I-PL-2.
Human VEGF 165 (hVEGF165) cDNA was PCR-amplified
from pBLAST49-hVEGF v2.0 (Invivogen, San Diego, CA)
using primers 5¢-CCTACCTAAGCTTACCGGTAGGA and
5¢-CTTATCATGTCTAGATAGCTCACC, digested with
HindIII and BglII and ligated to HindIII/BglII-cut pZ12I-
PL-2. The resulting plasmid was digested with MluI and
BamHI to recover a fragment containing hVEGF165 coding
sequence and minimal hIL-2 promoter fused to a tandem of
12 ZFHD1. This fragment was ligated to the largest fragment
of an MluI/BamHI-cut pLH-Z12I-PL version in which a
BamHI site was introduced at the multicloning site using the
QuickChange procedure and primer 5’-GCTTGCCCTGCA
GCG GGGGATCCACTAGTCGAGATCT. The resulting
plasmid was named pLHZ12-hVEGF165.
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All subcloning and mutagenesis steps were monitored by
restriction analysis and nucleotide sequencing. Plasmids
pZ12I-PL-2, pC4N2-RHS3H/ZF3, pL2N2-RHS3H/ZF3, and
pLH-Z12I-PL were obtained from ARIAD Gene Ther-
apeutics, Inc. (Cambridge, MA), under the terms of a mate-
rial transfer agreement.
Drugs
For in vitro experiments, rapamycin (LC Laboratories,
Woburn, MA) was dissolved in dimethyl sulfoxide and the
rapalog AP21967 (kindly provided by ARIAD Gene Ther-
apeutics, Inc.) was dissolved in 100% ethanol. For in vivo
injections, rapamycin or AP21967 were initially dissolved in
N,N-dimethylacetamide (DMA) as a stock solution (3mg/
ml) and then diluted to each specific concentration in a
mixture of 50% DMA, 45% polyoxythylene glycol (average
molecular weight of 400), and 5% polyoxyethylene sorbitan
monooleate. Intraperitoneal (ip) injections were in a total
volume of 50 ll. Rapamycin and AP21967 were administered
in vivo at doses of 1 and 10mg/kg, respectively.
Cell culture, transfection, and isolation of cell lines
The clonal mouse multipotent cells, C3H/10T1/2, clone 8
(ATCC Catalog Number CCL-226), were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) fetal bovine serum (FBS), 100U/ml penicil-
lin, and 0.1mg/ml streptomycin in a humidified 5% CO2
atmosphere at 37C. Subconfluent cultures were transfected
using Lipofectamine 2000 reagent (Invitrogen) following
manufacturer’s recommendations. C3H/10T1/2 transfor-
mants stably expressing pL2N2-Hsp70/12xZFHD1-TA were
selected using G418 (1200lg/ml). Stable clones were
screened for HS and rapamycin responsiveness after tran-
sient transfection with pZ12-fLuc. One day after lipofection,
cells were treated for 1 hr with 10 nM rapamycin or vehicle,
and then subjected to heat treatment at 45C for 30min in
a water bath. Cells were lysed and assayed for firefly lucif-
erase activity 24 hr after HS. A highly inducible clone that
exhibited negligible levels of fLuc activity after heat treat-
ment or exposure to rapamycin alone was isolated and then
transfected with pLHZ12-hVEGF165 or a combination of
pZ12-fLuc and Linear Hygromycin Marker (Clontech,
Mountain View, CA) at a 20:1 molar ratio. Clones were se-
lected using hygromycin B (600 lg/ml) and screened for
VEGF secretion or fLuc activity 1 day after applying the
aforementioned stimulation conditions. C3H/10T1/2 cell
lines exhibiting low background of fLuc activity or VEGF
secretion and strong induction exclusively after combined
HS and ligand treatments were termed C3H/10T1/2-fLuc
and C3H/10T1/2-VEGF, respectively. Clonal cells were
maintained in DMEM containing 10% FBS and 1% penicillin
and streptomycin under continuous selection with G418 and
hygromycin B.
Pooled human umbilical vein endothelial cells (HUVECs),
endothelial basal medium (EBM), endothelial growth me-
dium (EGM), and a solution for coating culture wares for
endothelial cells (ECs) growth were purchased from Angio-
proteomie (Boston, MA). HUVECs (passage number below
5) were plated at a density of 3.2 · 104 cells/cm2 in EGM.
After 24 hr, cells were washed with phosphate-buffered sa-
line (PBS) and cultured with EGM, or EBM-10% FBS condi-
tioned by C3H/10T1/2-VEGF cells. Media were routinely
replaced every 2 days. Cell viability was assessed using the
alamarBlue reagent (Biosource, Nivelles, Belgium) following
manufacturer’s recommendations.
Measurement of target gene activity
For in vitro experiments, cells were seeded at a density
of 1.5 · 104 cells/cm2. One day after, cells were exposed to
the indicated HS treatment in a thermostatically controlled
water bath in the presence of the drug or vehicle. Cells were
lysed using Passive Lysis Buffer (Promega), and protein ex-
tracts were assayed for fLuc activity using the Luciferase
Assay System (Promega) according to the manufacturer’s
recommendations. Luciferase light counts were detected in a
Monolight 2010 luminometer (BD Biosciences, San Jose, CA).
VEGF secretion was measured using a commercially avail-
able ELISA kit (R&D Systems, Inc., Minneapolis, MN). Lu-
ciferase activities and VEGF secretion were normalized after
measurement of total protein concentration in the cell lysates
using Bio-Rad Protein Assay (Bio-Rad Laboratories, Berke-
ley, CA).
Animal experiments
All procedures were approved by the University Com-
mittee on the Use and Care of Animals and were in com-
pliance with state and federal laws. For subcutaneous
implants, 1 million of C3H/10T1/2-fLuc or C3H/10T1/2-
VEGF cells were suspended in 450 ll of a serum-free DMEM
solution containing 10 or 7.5mg/ml of bovine fibrinogen
(Sigma-Aldrich, St. Louis, MO), respectively. About 50 ll of
20U/ml bovine thrombin diluted in DMEM (Sigma-Aldrich)
was added, and the mixture was immediately injected sub-
cutaneously into the backs of 4–5-week-old C3H/HeNCrl
mice (Charles River Laboratories, Inc., Wilmington, MA) in
the anterior or posterior location. Before injection, hair was
removed from injection areas by shaving and depilatory
treatment, and animals were anesthetized with isoflurane
(2% for induction and 1.5% for maintenance). During im-
plant polymerization, mice were kept stationary for 5min
and subsequently placed in the recovery cage. After 24 hr,
animals receiving heat treatment were anesthetized and heat
was administered to the lower-back implants by partial im-
mersion of the animal body in a water bath at 44.5C for the
indicated times. Drug or vehicle was administered 90min
before HS treatment. At retrieval, animals were euthanized,
injection areas were photographed, and implants including
surrounding skin and muscle layers were surgically re-
moved. The erythematous areas in photographs of the in-
jections areas were measured using Fiji, an open-source
image-processing package based on ImageJ. For determina-
tion of VEGF content in implanted constructs, fibrin explants
were excised, swirled in PBS, and homogenized in RIPA
buffer (Sigma-Aldrich) before being tested by ELISA.
Bioluminescence imaging
Mice were anesthetized with isoflurane, and 50 ll of a
solution of 40mg/ml D-luciferin (Promega) in PBS was in-
jected subcutaneously near the implant region. Immediately
after, animals were placed in the dark chamber for light ac-
quisition in an IVIS charge-coupled device camera system
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(Xenogen, Alameda, CA) and analyzed with the Living Im-
age 4.0 software (Xenogen). The region of interest covering
the implantation area was defined, and quantification of
light emission was measured.
Histology
Formalin-fixed samples were dehydrated through a series
of graded ethanols, xylol, and finally xylene, and embedded
in paraffin. Five-micrometer sections were deparaffinized,
rehydrated, and stained with hematoxylin and eosin (H&E)
or, alternatively, were subjected to immunohistochemical
staining using specific antibodies for von Willebrand factor
(vWF) or CD31. Briefly, sections were stained for vWF first
underwent antigen retrieval with 0.1M citrate buffer, pH 6.0,
at 95C for 20min. Endogenous peroxidases were quenched
by treatment with 1% H2O2 for 20min, and the slides were
then blocked for 1 hr with a buffer containing 2% (w/v)
bovine serum albumin (Sigma-Aldrich) and 2% (v/v) normal
sheep serum (Sigma-Aldrich). After rinsing with 0.05% (v/v)
Tween-20 in PBS (PBST), sections were incubated for 2 hr at
room temperature with anti-vWF rabbit polyclonal antibody
(AB7356; Millipore, Temecula, CA) or nonimmune rabbit
IgG (Vector Labs, Burlingame, CA) diluted to 5 lg/ml in the
blocking buffer. The slides were then rinsed in PBST and
processed using the Vectastain ABC rabbit peroxidase de-
tection kit and DAB substrate kit (both from Vector Labs),
following the manufacturer’s instructions. The slides were
counterstained with hematoxylin QS (Vector Labs), dehy-
drated, and mounted with Histomount (Invitrogen). Sections
stained for CD31 were treated similarly, except that antigen
retrieval was performed after the peroxidase quench and
consisted of a digestion with 40 lg/ml proteinase K for
15min at room temperature. The anti-CD31 rat polyclonal
antibody (ab56299; Abcam, Cambridge, MA) or a nonim-
mune rat IgG (Vector Labs) was diluted to 1.25 lg/ml.
Images of the sections were captured on an Eclipse 50i mi-
croscope (Nikon Instruments, Melville, NY) with 4· , 10 · ,
and 20 · objectives (Nikon) and a DP72 digital camera
(Olympus America, Inc., Center Valley, PA). Areas of vWF +
or CD31 + structures in imaged muscle were calculated using
Fiji software after digitally establishing a threshold for DAB
staining intensity normalized to H&E counterstain.
Statistical analysis
Statistical analysis was performed using Student’s t-test to
measure statistical differences between groups. Unless indi-
cated otherwise, experimental data are reported as means
and SDs of triplicate independent samples.
Results
In vitro characterization of a heat-activated
and rapamycin-dependent gene switch
Figure 1a outlines the operation of a Hsp-based,
rapamycin-dependent gene circuit. In this system, heat
treatment activates the human HSP70B promoter to drive
expression of a bimodular synthetic transactivator. This
factor has separate DNA-binding and activation domains
that are expressed as fusion proteins with the rapamycin-
binding domains of the human proteins FKBP12 and FRAP
(mTOR), respectively. Rapamycin reversibly cross links both
modular proteins, resulting in the reconstitution of a func-
tional transcription factor capable of inducing expression of a
target gene of choice. Target gene responsiveness is con-
trolled by a minimal IL-12 promoter supplemented with
ZFHD1 elements recognized by an engineered DNA-binding
domain (Pomerantz et al., 1995). These synthetic DNA ele-
ments were also inserted into the HSP70B RNA leader region
to confer both heat and autoactivated expression on the
linked transactivator gene. The highly potent activation do-
mains incorporated into this system, derived from the acti-
vation domain of the p65 subunit of human NF-jB and
human HSF1 (Schmitz and Baeuerle, 1991; Pollock et al.,
2000), typically lead to high levels of induced gene expres-
sion, whereas in the absence of rapamycin the system dis-
plays extremely low basal activity since the transactivator
modules have no affinity for one another in the absence of
dimerizer (Rivera et al., 1999, 2005; Auricchio et al., 2002). A
mutation of the rapamycin-binding region of the mTOR-ac-
tivation domain allows the use of certain rapamycin analogs
(rapalogs) to specifically heterodimerize the engineered
transcription factor without interfering with the activity of
endogenous mTOR (Pollock et al., 2002). Rapalogs are unable
to bind to endogenous mTOR protein and therefore have
little immunosuppressive or antiproliferative activity (In-
draccolo et al., 2006), yet are able to function as chemical
inducers of this system (Liberles et al., 1997; Stankunas et al.,
2003). Rapamycin and rapalogs were previously shown to
function in vivo after oral administration or ip injection
(Pollock et al., 2000).
To test the functionality of this expression system, we
generated a cell line (C3HT101/2-fLuc) that stably harbors a
firefly luciferase reporter gene (fLuc), under control of the
gene switch. In the absence of HS, increasing doses of het-
erodimerizer were unable to induce fLuc activity (Fig. 1b).
However, heating at 45C for 30min in the presence of ra-
pamycin or the rapalog AP21967 resulted in a clear concen-
tration-dependent induction of luciferase activity (Fig. 1b).
Consistent with previous reports, rapamycin was slightly
more active than AP21967, with half maximal induction seen
with 1 nM rapamycin versus 5 nM for rapalog (Koh et al.,
2006). As shown in Fig. 1c, a minimum of 20min at 45C was
required for induction of fLuc activity. Heat treatment for
longer than 35–40min led to degradation of the response,
likely due to cell damage. To characterize the kinetics of the
target gene induction, a time–course experiment was per-
formed. Peak levels of luciferase activity were detected 24 hr
after HS with values gradually decreasing at later times
(Fig. 1d). Withdrawal of rapamycin from induced cultures
accelerated the rate of decay. Control cultures consisting
of vehicle-treated cells with or without exposure to HS or
rapamycin-treated cells not exposed to hyperthermia showed
negligible levels of background luciferase activity for the
entire observation period, confirming the tight control of
target gene expression exerted by this gene circuit.
Heat-activated, rapamycin-dependent gene
expression in vivo
C3HT101/2-fLuc cells were suspended in a fibrin scaffold
and subcutaneously implanted on the backs of adult C3H/
HeNCrl mice. After ip administration of heterodimerizer
or vehicle, the lower back of each mouse was exposed to
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localized HS by partial immersion in a 44.5C water bath;
24 hr later, luciferase activity was assessed by biolumines-
cence imaging (Fig. 2). Heat activation and administration of
1mg/kg rapamycin or 10mg/kg AP21967 resulted in >250-
fold induction of fLuc activity. In contrast, fLuc activity in
upper-back implants that did not receive any thermal treat-
ment was below the limits of detection and indistinguishable
from implants in the vehicle-treated group (Fig. 2a). The
experiment presented in Fig. 2b was performed to determine
whether gene switch activity induced by a single HS could
be sustained in animals receiving a daily rapamycin dose
(1mg/kg ip) and whether activation could be reversed upon
discontinuation of heterodimerizer treatment. Biolumines-
cence image analysis revealed a progressive decrease of lu-
ciferase activity during the days following the peak of
induction. Similar to the in vitro result shown in Fig. 1d,
discontinuation of rapamycin administration 24 hr after ac-
tivation of the gene switch accelerated the decay of fLuc
activity, with the luminescent signal approaching basal un-
induced levels within 2 days of dimerizer withdrawal. Long-
term monitoring of heat-activated, rapamycin-dependent
gene switch functionality in vivo demonstrated that after
activation, fLuc levels remained elevated over uninduced
controls for at least 8 days in animals treated with rapamycin
every other day (Fig. 2c). To determine if transgene activity
can be repeatedly activated, mice in the HS/rapamycin
group were given a second HS exposure after 13 and 27
days. At both times, luciferase activity was reinduced within
24 hr and reached levels comparable those observed after
the initial rapamycin/HS exposure. Thus, the HS-activated,
rapamycin-dependent gene switch was shown to stringently
regulate target gene expression in vivo and was capable of
repeated activation over a 4-week period.
Gene switch regulation of VEGF secretion
To evaluate whether the Hsp-based, rapamycin-
dependent gene expression system is an appropriate tool for
delivery of a regenerative factor, we developed a cell line,
C3H/10T1/2-VEGF, stably harboring hVEGF165 under the
control of the gene switch. In vitro, engineered cells re-
sponded to thermal stress by increasing levels of VEGF se-
cretion in a heterodimerizer-dependent fashion (Fig. 3a).
Dose–response curves for rapamycin and AP21967 were
FIG. 1. Development and characterization of a heat-activated, rapamycin-dependent gene switch. (a) Outline of the two-
component heat shock protein (Hsp)-based circuit that employs a heterodimerizer-regulatable transactivator. (b) Ligand
concentration dependence. C3HT101/2-fLuc cells were treated with the indicated doses of rapamycin (Rm) or AP21967 (AP)
with ( + ) or without (- ) heat shock (HS) at 45C for 30min. Relative fLuc activities were assayed 24 hr after HS. (c) HS time
dependence. C3HT10-1/2-fLuc cells were exposed to vehicle (Vh), Rm, or AP (10 nM each), and then heat treated at 45C for
the indicated times. Relative fLuc activities were assayed 24 after HS. (d) HS and ligand dependence of gene switch. C3HT10-
1/2-fLuc cells were treated with 10 nM Rm or vehicle Vh with (+ ) or without (- ) heat treatment at 45C for 30min (HS). In
one set of Rm HS + cultures, the medium was changed to an Rm-free medium 24 hr after HS (Rm WD). Relative fLuc
activities were assayed at the indicated times after HS. *Significantly different from the Rm HS + group, p < 0.05. Relative fLuc
activity was expressed as the number of light units per microgram of cell lysate protein. Error bars depict mean+ SD.
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similar to those observed for induction of the luciferase re-
porter in Fig. 1. Similarly, a HS time of approximately 35min
was required for maximal VEGF induction (Fig. 3b). In
contrast to the longer exposure required for activation of
fLuc activity, elevated VEGF secretion was observed after as
little as 10min of hyperthermic stimulus. The VEGF ex-
pression system could also be reactivated after an initial
stimulation (Fig. 3c). In this experiment, cell culture media
were collected and replaced daily by fresh media, starting
24 hr after HS. Measurement of VEGF levels in the harvested
media revealed a time-dependent decrease in the rate of se-
cretion that decayed to basal levels after 6 days. Withdrawal
of rapamycin from induced cultures accelerated the rate of
decay such that VEGF levels were 30% of those seen in
samples with continued rapamycin treatment 2 days after
induction. A second HS treatment 1 week after the initial HS
was able to reinduce VEGF secretion to levels greater than
those achieved by the initial induction. To test whether in-
duced VEGF is biologically active, we rely on the premise
that this growth factor is an important mediator in EC pro-
liferation and survival (Gupta et al., 2002). HUVECs exposed
to the conditioned medium from induced C3H/10T1/2-
VEGF cells for 7 days exhibited metabolic activities similar to
those in cultures treated with commercial EGM and signifi-
cantly higher than HUVECs exposed to the medium ob-
tained from C3H/10T1/2-VEGF exposed to heat or
heterodimerizer alone (Fig. 3d).
Regulation of angiogenic activity and vascular
perfusion by the VEGF gene switch in vivo
A final series of experiments examined whether the VEGF
gene switch is active in vivo. C3H/10T1/2-VEGF cells en-
capsulated in an in situ polymerizable fibrin gel were sub-
cutaneously injected in the posterior dorsal region of C3H/
HeNCrl mice. Animals were treated with vehicle or rapa-
mycin with or without localized heat treatment (44.5C for
25min). After 24 hr, rapamycin-treated mice exposed to HS
exhibited a strong angiogenic response that increased with
time (Fig. 4a). Most obvious was an erythema that reached a
maximum average size of 1.12 – 0.51 cm2 and led to erosion
of the skin after 1 week. None of the animals exposed to
either HS or rapamycin alone showed any evidence of skin
lesions in the implant area. Quantification of VEGF con-
tained in explanted fibrin constructs revealed a 150-fold in-
crease of protein levels in the rapamycin-treated group 1 day
after localized hyperthermia, as compared with implants not
subjected to heat treatment (Fig. 4b). Although VEGF levels
decayed at later times, they consistently remained elevated
in rapamycin/HS mice relative to controls. Histological
FIG. 2. In vivo performance of heat-activated and rapamycin-dependent gene switch. (a) In vivo induction. C3HT10-1/2-
fLuc cells were subcutaneously implanted on the backs of C3H/HeNCrl mice using an in situ-polymerizable fibrin scaffold.
Animals were injected with rapamycin (Rm), AP21967 (AP), or vehicle (Vh), and lower-back implants were immersed in a
water bath at 44.5C for 20min (HS + ). Upper-back implants did not receive heat shock (HS - ). Bioluminescence images (BLI)
were obtained 24 hr after HS (left), and average radiance from the region of implantation was analyzed using specific
software for BLI signal quantification (right). (b) Periodic administration of heterodimerizer maintains the induced state of
C3HT10-1/2-fLuc cells in vivo. Animals implanted with C3HT10-1/2-fLuc cells were injected with Rm or Vh, subjected to HS
at the implantation site, and then administered daily with Rm or Vh as in the initial treatment. In another set of animals, Rm
administration was discontinued 1 day after HS (Rm WD). Average radiances from implants subjected to hyperthermia were
measured by BLI at the indicated times after HS. *Significantly different from the Rm group, p< 0.05, n= 4/group. (c) Long-
term performance and reactivation of the gene switch. Mice were implanted as in (a) and treated with Rm or Vh with (+ ) or
without (- ) HS. fLuc activity of implanted cells was monitored by BLI measurements at the times indicated after first HS. Rm
or Vh were administered every other day after HS treatment. Black arrow and open arrow indicate the day that a second or a
third HS was performed, respectively, after Rm or Vh administration. Error bars depict mean + SD. Color images available
online at www.liebertpub.com/hgtb
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sections of skin overlying the implant or muscle from be-
neath the fibrin–cell construct were obtained 3 days after
induction and immunohistochemically stained for vWF, a
glycoprotein involved in hemostasis that is exclusively ex-
pressed by ECs (Yamamoto et al., 1998). Strong vWF staining
was observed in skin and muscle sections from the HS-acti-
vated, rapamycin-treated group (Fig. 4c). Staining for vWF
dissipated with distance from the activated implant. In ad-
dition, muscle subjacent to activated implants showed up to
a 300-fold increase of the vWF + area compared with control
implants. Only weak staining for vWF was observed for fi-
brin-C3HT10-1/2-VEGF constructs exposed to either HS
or rapamycin alone. It is worth noting the presence of
mononuclear cell infiltrates exclusively in the muscular lay-
ers associated with activated implants (Fig. 4c), likely indi-
cating a local increase in vascular permeability, a well
characterized response to VEGF (Connolly et al., 1989). The
increased hyperemic surface of the gluteal muscles from HS/
rapamycin-treated group shown in Fig. 4c is also consistent
with a VEGF-induced increase in vascular permeability. Ex-
pression of CD31, also known as platelet EC adhesion mole-
cule 1, is indicative of microvasculature (Albelda et al., 1991;
Horak et al., 1992). To account for tissue differences in EC
distribution after activation of the gene switch, we performed
CD31 immunostaining of muscle sections underlying the fi-
brin constructs. The ratio of CD31+ structures to muscular
fibers quantified in the samples showed a threefold increase in
activated implants (Fig. 4c), while no substantial differences
were found between the samples biopsied from uninduced
control groups. Taken together, these results show that the
engineered gene switch is capable of selectively inducing bi-
ologically active VEGF in vivo, leading to dramatic changes in
microvasculature dynamics and blood vessel permeability.
Discussion
A particularly attractive aspect of ligand-dependent,
HS-inducible gene expression systems is that they can
FIG. 3. Gene-switch-mediated in vitro induction of bioactive vascular endothelial growth factor (VEGF). (a) VEGF secretion
as a function of ligand dose. C3HT10-1/2-VEGF cells were treated with the indicated concentrations of rapamycin (Rm) or
AP21967 (AP) with (+ ) or without (- ) heat treatment at 45C for 30min (HS). Media were collected 24hr after HS and VEGF
secretion was measured. (b) VEGF secretion as a function of HS intensity. C3HT10-1/2-VEGF cells were exposed to vehicle (Vh),
10 nM Rm, or AP and then heated at 45C for the indicated times. VEGF secretion was assayed in media collected 24hr after HS.
Relative VEGF secretion was expressed as picogram of VEGF secreted per microgram of cell lysate protein. (c) Time–course of
VEGF secretion. C3HT10-1/2-VEGF cells were treated with Vh or 10nM Rm, with (+ ) or without (- ) heat treatment at 45C for
30min (HS) and further cultured for 24hr. Media were collected daily after HS and replaced with a fresh medium containing
Rm or Vh as in the initial treatment. A set of cultures (RmWD) was fed with a fresh medium and treated with Vh 1 day after HS
treatment in the presence of Rm. Black arrow indicates the day that a second HS was performed. *Significantly different from
the Rm HS+ group, p<0.05. #Significantly different from Vh HS- or Rm HS- groups, p< 0.05. (d) Bioactivity of induced
VEGF. C3HT10-1/2-VEGF cells cultured in EBM in the presence of Vh or 10nM AP with (+ ) or without (- ) HS. Conditioned
media (CEBM) were collected 24hr after HS. HUVECs were cultured with CEBM or EGM for 1 week and cell viability was
measured. *Significantly different from Vh HS- , Vh HS+ , and AP HS- groups, p< 0.05. Error bars depict mean+ SD.
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theoretically use hyperthermia to trigger the expression of
any number of ligand-activated transcription factors that, in
the presence of the appropriate inducer, can each activate a
unique promoter and associated transgene. Our initial
demonstration of this concept used HS to induce a mife-
pristone-activated transcription factor (Vilaboa et al., 2005).
Here we describe a second HS-inducible system that com-
bines the stringent control of rapamycin/rapalog-dependent
transactivators with the spatial control provided by hyper-
thermic induction. This system requires both HS and ligand
for transcriptional activity and has extremely low back-
ground in the uninduced state. Luciferase or VEGF expres-
sion was shown to decay to basal levels within 1 week, but
could be repeatedly reactivated by subsequent heat treat-
ments. Furthermore, use of this approach to induce VEGF
in vivo resulted in clear temporal and spatial control of a
biological response.
Polymeric scaffolds have previously been used to directly
deliver bioactive protein cargos such as recombinant VEGF,
BMPs, insulin-like growth factors, fibroblast growth factors,
FIG. 4. Gene switch induction of vascular endothelial growth factor (VEGF) in vivo. (a) In vivo induction. C3HT10-1/2-
VEGF cells were subcutaneously implanted on the backs of C3H/HeNCrl mice as in Fig. 2. Animals were treated with
rapamycin (Rm) or vehicle (Vh), and the lower-back implants were either kept at ambient temperature (HS - ) or exposed to
heat treatment at 44.5C for 25min (HS + ). Animals were photographed 1–7 days after HS, and the extent of skin lesions
(indicated as erythematous area in cm2) was calculated (n = 4/group). (b) Measurement of induced levels of VEGF in vivo.
Subcutaneous fibrin implants were explanted 1–6 days after HS, and processed to quantify the levels of secreted VEGF.
Growth factor levels were expressed as picogram of protein per wet weight of fibrin (g). *Significantly different from the HS -
group, p< 0.05, n= 3/group. (c) Histology. Cross sections of skin overlying the fibrin/C3HT10-1/2-VEGF cell implants (left
column; scale bar = 50 lm) and muscle underlying the implant (central and right columns; scale bar = 100 and 50 lm, re-
spectively) were obtained from Rm- or Vh-treated mice 3 days after HS. Samples were processed for immunohistochemical
detection of von Willebrand factor (vWF) or CD31. Open arrows indicate infiltration of mononuclear cells. Black arrows
indicate CD31 + capillary-like structures. Quantification of the area of vWF+ or CD31 + structures in muscle sections was
calculated by image analysis software and indicated as arbitrary units. Microscopy images of muscle surface in contact with
fibrin construct are presented as boxed images in the central column (scale bar = 25lm). Error bars depict mean+ SD.
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and/or platelet-derived growth factors. The proteins are
typically encapsulated within scaffolds or bound to the
surface via electrostatic interactions or covalent conjugation.
Methods of regulating growth factor release from such
scaffolds generally include tuning the spontaneous, cell-
mediated, or physically inducible (e.g., light, enzyme, or
drug) degradation of the scaffold (Leach et al., 2006; Kempen
et al., 2009; Mercado et al., 2009; Jay et al., 2010; Singh et al.,
2012). Although some success has been achieved with these
approaches, they have certain inherent limitations, including
restriction in the amount and stability of growth factor in-
corporated into the scaffold, inability to vary release kinetics
in real time to compensate for a changing regeneration en-
vironment, and difficulties with repeated on/off control of
factor release. The regulated gene expression system we
developed has many advantages over these protein delivery
schemes. Specifically, scaffolds containing a uniform distri-
bution of genetically modified cells can be implanted within
a regeneration site and desired subregions within the scaf-
fold can be activated by local thermal treatment. In addition,
concentration and duration of growth factor delivery can be
controlled by both the extent of HS and the concentration of
rapamycin/rapalog ligand.
Prior studies showing that rapamycin-dependent gene
circuits are able to precisely control the temporal availability
of therapeutic transgenes (i.e., growth hormone, insulin,
erythropoietin, IFNa, BMP-2, or cell-line derived neuro-
trophic factor) (Rivera et al., 1999, 2005; Auricchio et al., 2002;
Johnston et al., 2003; Indraccolo et al., 2006; Koh et al., 2006;
Hadaczek et al., 2011) indicated that this is an excellent
ligand-activated system to combine with Hsp-based systems.
Detailed in vitro characterization of C3HT101/2-fLuc and
VEGF cells showed strong thermal inducibility of the gene
switch in the presence of nanomolar concentrations of het-
erodimerizer, but negligible transgene expression when one
or both stimuli are absent. Consistent with previous reports
( Jullien et al., 2007), we found the activity of AP21967 to be
approximately one-fifth the activity of rapamycin. However,
this compound does not inhibit endogenous mTOR and has
less than one thousandth the immunosuppressive activity of
rapamycin (Indraccolo et al., 2006). Therefore, it is a preferred
ligand to activate this system in vivo.
Cell lines expressing either fLuc or hVEGF165 under the
control of the HS- and rapamycin-activatable gene circuit
demonstrate that this switch is capable of regulating the
expression of various transgenes. Interestingly, we found
that these cell lines exhibited different sensitivities to hy-
perthermic stimulus. In the presence of heterodimerizer,
VEGF-engineered cells secreted detectable quantities of
hVEGF with HS exposure times as short as 10min, whereas
fLuc-engineered cells required twice the time to yield mea-
surable increases in luciferase activity. This difference is
particularly impressive given the substantially higher sensi-
tivity of luciferase assays compared with ELISA. Both lines
were derived from a common parental line harboring stably
integrated copies of the transactivator that is expressed from
an activated HSP70B promoter, which suggests that the ob-
served differences in inducibility are not related to the HS-
sensitive component of the switch. Rather, we attribute this
divergent behavior to variations in the stability of the
transgene mRNAs and/or protein products. These results
underscore the importance of endogenous mechanisms of
post-transcriptional and/or post-translational (trans)gene
regulation in the overall behavior of a given transgene.
To assess the functionality of this gene switch in vivo, cells
containing the inducible system were encapsulated in a
biodegradable fibrin hydrogel scaffold. This scaffold material
is approved for clinical use by the U.S. Food and Drug As-
sociation, polymerizes by an enzymatic mechanism under
mild conditions, and permits facile delivery by subcutaneous
injection. Fibrin and its degradation products also support
angiogenesis and tissue repair (Amrani et al., 2001), and can
be used as an autologous scaffold to support the growth of
seeded cells with low risk of a foreign body reaction (Shaikh
et al., 2008). We chose to use fibrin in these studies for the
reasons described above, but our approach to controlling the
delivery of regeneration growth factors is, in principle,
compatible with many currently used natural and synthetic
tissue engineering scaffolds such as collagen and alginate
hydrogels and biodegradable polymers including poly lactic-
co-glycolic acid. The only possible restrictions we anticipate
would be related to the thermal absorption properties of
certain scaffolds such as ceramics that might draw thermal
energy away from targeted cells and disrupt activation.
Translation of this platform technology for therapeutic
applications will require delivery of the switch components
to a clinically relevant cell source, such as primary mesen-
chymal progenitor cells. We generated clonally derived cell
lines harboring the gene switch from a C3H10T1/2 parent
line because these cells resemble, in terms of multipotency,
primary progenitor cells, are readily available, and elicit
modest immune responses when implanted in syngeneic
(C3H) immunocompetent mice (unpublished observations).
Thus, the C3H10T1/2 lines served as convenient and con-
trolled experimental systems for evaluating the performance
of the gene switch in vitro and in vivo. Ongoing studies are
focused on the construction of viral vectors capable of effi-
ciently transducing primary cells with the gene switch and
characterizing its performance in a population of transduced
cells. Evaluation of switch function in primary cells and
in vivo models of tissue injury (e.g., hind limb ischemia) will
be important next steps in assessing the clinical potential of
this platform.
In vivo activation of C3HT101/2-derived cells seeded
within an injectable fibrin scaffold demonstrated the ability
of the heat-activated rapamycin-dependent gene switch to
induce transgene activity at specific sites exposed to hyper-
thermia. The stringent requirement for both heat and di-
merizer stimuli for activation prevents the inadvertent
production of therapeutic proteins at distal sites or as a
consequence of physiological hyperthermia associated with
inflammation, strenuous exercise, or fever. Administration of
a heterodimerizer modulates the temporal window during
which the gene circuit remains active through the auto-
regulatory loop defined by the Hsp70B/12xZFHD1 pro-
moter cassette, thereby ensuring the replacement synthesis of
the transactivator. Heterodimerizer withdrawal in vitro or
in vivo increases the rate of decay of induced protein. This
mechanism does not interfere with the ability of the gene
circuit to be reactivated, since maximal transgene induction
was seen after successive thermal treatments in the presence
of heterodimerizer. This approach was also able to control
the release of bioactive VEGF from engineered scaffolds, as
evidenced by the local response of ECs to conditioned
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medium in vitro and the vascular response observed in vivo.
In the latter case, the host tissue response to induced VEGF
was characterized by increased vWF and CD31 staining in-
dicative of vascular reorganization and mononuclear cell
infiltration into areas adjacent to activated implants. These
signs of increased vascular permeability and hyperemia were
macroscopically visible as an erythematous wound bed on
muscle and skin, a clear indication that the induced VEGF
was biologically active in vivo.
Our data indicate that levels of transgene production can
be modulated by duration of hyperthermia and hetero-
dimerizer dose. Future studies will focus on fine-tuning re-
generative factor release kinetics and localization by
precisely controlling thermal dose and spatial localization.
This can be achieved using focused ultrasound heating, a
technology that can be combined with magnetic resonance
temperature imaging to guide the deposition of thermal en-
ergy and gene activation (Deckers et al., 2009). The gene ex-
pression system we developed holds much promise for
applications where the temporal and spatial control of VEGF
delivery is desired such as in ischemia or applications where a
vascular bed is needed for tissue regeneration. This approach
is to be contrasted with the systemic delivery of VEGF where
hypotension, tachycardia, and reduced cardiac output are
common side effects (Yang et al., 1996, 1998). Moreover, the
heat- and heterodimerizer-dependent system may be used in
combination with the previously described Hsp-based and
mifepristone-dependent system to sequentially control the
expression of two transgenes in a regenerative medicine sce-
nario where precise timing and localization of therapeutic
factors expression is critical for therapeutic impact.
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